the firm's post-grant practitioners are some of the most experienced in the country.

Andrew M. Ollis
Arthur I. Neustadt
Kasumi  Kanetaka
Stephen G. Baxter, Ph.D.
Christopher  Ricciuti
Ryan W. Smith
Chika (Teranishi) Iitoyo
John F. Presper
Surinder  Sachar
Long  Phan, Ph.D.
Christopher I. Donahue
Teddy S. Gron
Norman F. Oblon
Craig R. Feinberg
Yin Y. Nelson, Ph.D.
Michael R. Casey, Ph.D.
Yanwen  Fei
Tia D. Fenton
Colin B. Harris
Erik M. Stang, Ph.D.
Stefan Uwe  Koschmieder, Ph.D.
Maki  Saitoh
Eric W. Schweibenz
Steven B. Chang
Jay E. Rowe, Jr., Ph.D.
Aldo  Martinez
Carl E. Schlier
Thomas M. Cunningham, Ph.D.
Robert W. Downs
Soumya  Panda
Elissa L. Sanford
Jenchieh (Joseph) Yuan
Vincent K. Shier, Ph.D.
Ching-Cheng (Tony)  Chang
Eckhard H. Kuesters
Jeffrey B. McIntyre
Robert  Tarcu
Aristotelis M. Psitos
John S. Kern
Alexander B. Englehart
Kevin Ross  Davis
Sameer  Gokhale
Diane  Jones
Yuki  Onoe
Yuanyi (Alex) Zhang
Bogdan A. Zinchenko
J. Derek  Mason, Ph.D., CLP
John  Sipos
Brian B. Darville
Derek  Lightner, Ph.D.
Nanlin  Wang, Ph.D.
Kevin L. Hartman, Ph.D.
Charles L. Gholz
Nicholas  Rosa, Ph.D.
Edwin D. Garlepp
Tao  Feng, Ph.D.
Frank J. West
Jianping (James)  Wu
James R. Love
Marina I. Miller, Ph.D.
Akihiro  Yamazaki
Peifang  Tian, Ph.D.
Daniel J. Pereira, Ph.D.
David M. Longo, Ph.D.
Dale M. Shaw
Kevin M. McKinley
Grace E. Kim
Johnny  Ma
Philippe J.C. Signore, Ph.D.
Kurt M. Berger, Ph.D.
Alec M. Royka
Robert T. Pous
Matthew H. Everhart, Ph.D.
Yorikatsu  Hohokabe, Ph.D.
Anna Z. Lloyd
Richard D. Kelly

Technologies

Artificial Intelligence (AI)
Artificial Intelligence (AI)
Digital Health
Digital Health
Energy & Renewables
Energy & Renewables

Fast Facts

About Our

Law Firm

About Our Law Firm

Headquartered within steps of the USPTO with an affiliate office in Tokyo, Oblon is one of the largest law firms in the United States focused exclusively on intellectual property law.

Get to know our

History

Get to know our History

1968
Norman Oblon with Stanley Fisher and Marvin Spivak launched what was to become Oblon, McClelland, Maier & Neustadt, LLP, one of the nation's leading full-service intellectual property law firms.

Our Local and

Global Reach

Our Local and Global Reach

Outside the US, we service companies based in Japan, France, Germany, Italy, Saudi Arabia, and farther corners of the world. Our culturally aware attorneys speak many languages, including Japanese, French, German, Mandarin, Korean, Russian, Arabic, Farsi, Chinese.

A few of our

ACCOLADES

A few of our ACCOLADES

Oblon's professionals provide industry-leading IP legal services to many of the world's most admired innovators and brands.

OPPORTUNITIES FOR YOUR

Career

OPPORTUNITIES FOR YOUR Career

From the minute you walk through our doors, you'll become a valuable part of a team that fosters a culture of innovation, client service and collegiality.

A few ways to

GET In Touch

A few ways to GET In Touch
US Office

Telephone: 703-413-3000
Learn More +


Tokyo Office

Telephone: +81-3-6212-0550
Learn More +

Downloadable

Patent Forms

Downloadable Patent Forms

The United States Patent and Trademark Office (USPTO) issued final rules implementing the inventor's oath or declaration provisions of the America Invents Act (AIA) on August 14, 2012.

USPTO Announces COVID-19 Prioritized Examination Pilot Program for Small and Micro Entities

  • May 8, 2020
  • Firm News

On Friday, May 8, 2020, the USPTO issued a release announcing a new COVID-19 Prioritized Examination Pilot Program, stating:

Under this new pilot program, the USPTO will grant requests for prioritized examination to applicants that qualify for small or micro entity status without payment of the typical fees[ of ~$2,000 and ~$1,000, respectively, ]associated with other prioritized examination. In addition, the USPTO will endeavor to reach final disposition of applications in this program within six months if applicants respond promptly to communications from the USPTO.

To qualify for the new program, the claims of an application must cover a product or process that is subject to U.S. Food and Drug Administration (FDA) approval for use in the prevention and/or treatment of COVID-19. See the Federal Register Notice for more information.

Please contact us if you have any questions regarding this item, noting that in light of the coronavirus pandemic, our office in Alexandria, Virginia has transitioned to teleworking in order to seamlessly continue the Firm's operations for our clients.